

ceribell[®]

Corporate Presentation

February 2026

Forward Looking Statement

This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, about the Company and its industry. These statements and the outcomes of the events they describe involve substantial risks, uncertainties and potentially inaccurate assumptions, some of which cannot be predicted or quantified. All statements other than statements of historical facts contained in this presentation, including statements regarding the Company's strategy, financial guidance and projections, future results of operations and financial performance, future operations, projected costs, prospects, plans, objectives, expected products, market size, market expansion, growth opportunities and competitive position, as well as assumptions relating to the foregoing, are forward-looking statements. In some cases, you can identify forward-looking statements by words such as "may," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "goal," "objective," "seeks," "aims," "forecasts," "guidance" or "continue" or the negative of these words or other similar terms or expressions that concern the Company's expectations, strategy, plans, or intentions.

The Company cautions you that the foregoing list does not contain all of the forward-looking statements made in this presentation. You should not rely upon forward-looking statements as predictions of future events, future financial performance or future trends. The Company has based the forward-looking statements contained in this presentation primarily on its current expectations, estimates, forecasts, and projections about future events and trends that it believes may affect its business, financial condition, results of operations, and prospects. The Company cannot guarantee or ensure that the future results, performance, events, circumstances or any other outcome expressed, anticipated or reflected in the forward-looking statements will be achieved or occur in whole or in part. Actual results, events, or circumstances could differ materially from those described or assumed in the forward-looking statements. Moreover, the Company operates in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for the Company to predict all risks and uncertainties that could have an impact on the forward-looking statements in this presentation. This presentation contains estimates, projections, and other information concerning the Company's industry and its business, as well as data regarding market research, estimates, and forecasts prepared by its management or third parties. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties. These data and the industry in which the Company operates are subject to a high degree of uncertainty and risk due to a variety of factors which could cause results to differ materially from those expressed in these estimates, publications, and reports made by third parties or the Company.

Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market acceptance and adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand and customer trends; the manufacturing of a substantial number of our product components and their assembly in China and Vietnam; product defects and related liability; the complexity, timing, expense, and outcomes of clinical studies; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; delays in regulatory, litigation or other matters affecting our business, and other risks and uncertainties, including those described under the heading "Risk Factors" in our Quarterly Reports on Form 10-Q, Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission ("SEC"). These filings, when made, are available on the Investor Relations section of our website at <https://investors.ceribell.com/> and on the SEC's website at <https://sec.gov/>.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect new information or the occurrence of unanticipated events, except as required by law. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments it may make. In addition, the results of studies referenced in this presentation concerning the Clarity algorithm apply only to the algorithm version that was in use at the time of the analysis and do not reflect subsequent algorithm updates. Most studies referenced in this presentation were conducted with small sample sizes and were not powered for statistical significance, did not control for other clinical variables, or have other design limitations (e.g., the studies may be retrospective and are not randomized controlled trials). In addition, some of the studies were sponsored, funded or supported by the Company or involved employees or consultants of the Company.

Trade names, trademarks and service marks of other companies appearing in this presentation are the property of their respective owners. Solely for convenience, the trademarks and trade names referred to in this presentation appear without the ® and ™ symbols. This does not indicate, in any way, that the Company will not assert its rights, and the rights of any applicable licensor, to these marks and tradenames, to the fullest extent under applicable law.


By attending or receiving this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the Company's market position and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of its business.

AI-Powered Point-of-Care EEG Platform Targeting Serious Neurological Conditions in the Acute Care Setting



Large & Expanding Potential Market Opportunity

FY25 Financial Highlights



\$89.1M
Revenue

36%
YoY Revenue Growth

88%
Gross Margin

*As of December 31, 2025

Ceribell's Three Growth Horizons

NOW

**Seizure Management
in the Acute Care Setting**

- ✓ *Become Standard of Care*

\$2.5B U.S. SEIZURE TAM*

NEAR TERM

**Make EEG a New Vital Sign
In Acute Care**

- ✓ *Indication Expansion in ICU and ED*
- ✓ *Other Acute Care Clinical Settings*

SIGNIFICANT POTENTIAL, INCREMENTAL MARKET OPPORTUNITIES

LONGER TERM

**Develop Solutions for
Use Beyond the
Acute Care Setting**


- ✓ *New Clinical Settings*
- ✓ *Biomarkers for Non-Acute
Neurological & Psychiatric
Conditions*

*Inclusive of adult, neonate and pediatric seizure U.S. market.


Targeting Seizures in the Acute Care Setting

Epileptic Seizures

Seizures in Acute Care (ICU & ED)



Seizures Are Highly Prevalent in Critically-Ill Patients and Often Go Undiagnosed




up to **92%**
of seizures in the ICU
are non-convulsive^{2,3}

EEG required for diagnosis


1. Herman, S.T., et al. (2015) J Clin Neurophysiol. 32(2):87-95
2. Claassen, J., et al. (2004). Neurology. 62(10):1743-1748
3. Rudin, D., et al. (2011) Epilepsy Res. 96(1-2):140-50

"Time is Brain"

STATUS EPILEPTICUS ALL-CAUSE MORBIDITY & MORTALITY RATE¹



PATIENT RESPONSE RATE TO FIRST-LINE TREATMENT²



1. Young, G.B., et al. (1996). Neurology, 47(1):83-89
2. Lowenstein, D.H., et al. (1993) Neurology, 43(3 Pt 1):483-488

Guidelines and Recommendations Include Timely EEG to Detect and Manage Seizures Across Different Disease States

2012

NEUROCRITICAL
CARE SOCIETY

EEG should be initiated **within 15-60 minutes** to “evaluate for NCSE if [patient is] not waking up after clinically obvious seizures cease.”¹

2020

American **Heart** Association

“Recommend **promptly performing and interpreting EEG** for the diagnosis of seizures in **all comatose patients** after the return of spontaneous circulation (ROSC)” from **cardiac arrests**.²

2021

American **Stroke** Association

“**EEG** [is recommended] for a *change in mental status* or depressed mental status out of proportion to the **[ischemic] stroke**.”³

2023

American **Stroke** Association

“Monitoring with continuous EEG can detect nonconvulsive seizures, especially in **[aneurysmal subarachnoid hemorrhage] patients** with depressed consciousness or fluctuating neurological examination.”⁴

1. Brophy, G., et al. (2012) Neurocrit Care. 17(1):3-23
2. Panchal, A.R., et al. (2020) Circulation. 142(suppl 2):S366-S468

3. Perman S.M., et al. (2024) Circulation 149(5):e254-e273
4. Green, T.L., et al. (2021) Stroke 52(5):e179-e197

Conventional EEG Has Significant Limitations in the Acute Care Setting

Overview of EEG

An EEG is a non-invasive tool used to measure and display electrical activity in the brain



*Designed for use in the **outpatient setting**, primarily for managing epilepsy patients*

Conventional EEG systems were not designed for the acute care setting


Hardware & Access Challenges

- ❌ Requires EEG Technician (Typically 9-5 Monday – Friday)
- ❌ Long Set-Up Process

Interpretation Challenges

- ❌ Requires Interpretation by a Specially-Trained Neurologist
- ❌ Continuous Monitoring Rarely Performed in Practice

Clinical Reality: Conventional EEG is Not Suited for the Acute Care Setting and Leads to Long Delays




1. Gururangan, K., et al. (2016) *Clinical Neurophysiology*. 127(10):3335-3340. Maximum time from EEG order to arrival and set-up
2. Vespa, P., et al. (2020) *Crit Care Med*. 48(9):1249-1257. Median time from EEG order to arrival and set-up

3. Quigg, M. et al. (2001) *J Clin Neurophysiol*. 18(2):162-165. Range of time from request to interpretation
4. Gavvala, J., et al. (2014) *Epilepsia*. 55(11):1864-1871

Ceribell EEG System: Suspicion to Diagnosis in Minutes, Enabling Earlier & More Accurate Treatment

The **ceribell**[®] System




1. Yazbeck et al. (2019) *Journal of Neuroscience Nursing*
2. Hobbs et al. (2018) *Neurocritical Care*
3. Eberhard et al. (2023) *Clinical Nursing Focus*

The **ceribell**[®] System

Combining highly portable, simple-to-use and rapidly deployable hardware with AI-powered algorithms

Ceribell EEG Headband



Ceribell EEG Recorder



Ceribell EEG Portal




AI-powered Seizure Detection Algorithm



Clarity: Our Proprietary AI-Powered Seizure Detection Algorithm

clarity®



✓ Bed-side Alert

✓ Real-time feedback on response to medication

✓ Provides seizure burden to facilitate EEG reading for neurologists

Ceribell Supports Precise Patient Care for SE: Expediting Diagnosis and Continuously Monitoring




Lorazepam 00:11:49



Lorazepam 00:27:48



Levetiracetam 03:48:01



Evidence-Based Clinical & Economic Benefits

47 Peer-Reviewed Publications & 97 Abstracts*

Study Findings

Outcome	convEEG (N = 62)	Ceribell (N = 62) ²	Δ Delta	P- Value
Median door-to-EEG time (hours)	25.3	5.9	19.4 hours faster door-to-EEG time	p < 0.0001
Median ICU LOS	8.0 Days	3.9 days	4.1 days shorter ICU LOS	P = 0.003
mRS ³ greater than or equal to 4 at discharge	76%	58%	18% better clinical outcomes⁴	p = 0.047

SAFER Study Overview

The Seizure Assessment and Forecasting with Efficient Rapid-EEG (SAFER-EEG) study is a multisite retrospective study of adult patients who received EEG during hospital stay. Most centers had 24/7 conventional EEG with technician onsite or on-call.

Study Sites :

- Yale University
- Mass General
- University of New Mexico

* As of December 31, 2025

1. Desai, M., et al. (2024) Neurocrit Care.

2. The cohorts were matched 1:1 with propensity scores to have equivalent age, admission scores, diagnosis group and seizure suspicion.

3. The Modified Rankin Scale (mRS) is a 6-point disability scale with possible scores ranging from 0 to 5. 0 is healthy and 5 is severe disability. A separate category of 6 is usually added for patients who expire.

4. Using mRS greater than or equal to 4 at discharge as an indicator of functional disability. Results with Ceribell vs. conventional EEG.

New for 2026: Pediatric & Neonate Indication Expansion



- Received FDA clearances for Clarity algorithms for age 1+ and neonate, including pre-term in 2025

- Unlocked **incremental \$400M market opportunity**, including ~280 children's hospitals targets



- Initiated successful pilots in 2025; **full launch in Q2 2026**

Seizures in Critically Ill Neonates are Common, Requiring EEG for Accurate Diagnosis

Diagnostic challenges can lead to under- and over-treatment



up to **90%** of neonatal seizures are non-convulsive^{1,2}




up to **73%** of clinically observed “seizures” are not seizures³

“We suggest cEEG use to monitor neonates at risk for seizure **in the absence of clinically evident seizures.**”

— American clinical Neurophysiology Society

Seizures are the most common neurological emergency in newborns



1. Murray, D.M., et al. (2008). Arch Dis Child Fetal Neonatal Ed. 93:F187-F191

2. Massey, S., et al. (2018). Seminars in Fetal & Neonatal Medicine. 23(2018):168-174


3. Sheth, R., et al. (1999). J Perinatol. 19(1):40-3

4. Yan, K., et al. (2023). Jama Network Open. 6(7):e2326301

Neonatal Seizures Require Urgent Diagnosis and Management


1 hour in seizure is associated with **worse language and neurocognitive impairment**¹

Predicted Language Score at 18 Months (Bayley-III)



Just **1 hour** delay to treat seizure may lead to **higher seizure burden**³

Median Seizure Burden



1. Alharbi, H.M., et al. (2022). Neurology. 100:e1976-e1984
2. Johnson, S, et al. (2014). Pediatr Res 75. 670-674

3. Pavel, A.M., et al (2021) J Pediatr. 243:61-68.e2

Business Model: Two Sources of Recurring Revenue

~25% Subscription

(SaaS + loaned capital)

clarity[®]

+



+



AI Algorithm
SaaS

Recorder
Capital

Portal
SaaS



~75% Product

(single-patient disposable)




Single-Use Headband
Disposable



Rapid Revenue Growth & Projectable Business Model

Quarterly Revenue


(\$ in million)



Significant Opportunity For Continued Growth Within Core Seizure Market


3%

of addressable
Market*



11%

hospital penetration*




Ceribell is currently active in only
647 out of roughly 6,000 hospitals
providing acute care services

x

30%

within existing accounts*



Ceribell's top customers use
approximately **3x the number of
devices** as average customers,
when controlling for hospital size

2026 Commercial Growth Drivers in Core Seizure Market



Account Acquisition

- Execute on proven account acquisition strategy
- Drive productivity of recently expanded commercial infrastructure
- Expand in VA
- Build out health system infrastructure and playbook
- Expand to Children's Hospitals



Drive Utilization in Existing Accounts

- Expand to new departments, ER, ICUs
- Train more providers in all shifts
- Integrate Ceribell into various patient population protocols based on established guidelines
- Expand to NICU, PICU, and Ped ER

Ceribell's Three Growth Horizons



\$2.5BN US SEIZURE TAM*

SIGNIFICANT POTENTIAL, INCREMENTAL MARKET OPPORTUNITIES

*Inclusive of adult, neonate and pediatric seizure U.S. market.

Ceribell's Goal: Make EEG A New Vital Sign



ceribell[®]



Stroke



Seizure



Delirium



Other

Moving Beyond Seizure in the Acute Care Setting

Delirium



**Received FDA Clearance:
Delirium Algorithm**

Submitted NTAP application, based on previously received Breakthrough Designation

Unlocks >\$1B market opportunity¹

Stroke



**Received FDA Breakthrough Designation:
LVO stroke detection algorithm in inpatient setting**

Delirium Represents a Significant Unmet Need

Delirium, defined as an acute change in attention and awareness, often called “**acute brain failure**”

High Prevalence

- **3+ million** patients in the US¹⁻⁴
- **~30%** of Intensive Care Unit patients⁵
- up to **80%** of mechanically ventilated patients⁶

Poor Clinical Outcomes

- 1 ICU delirium day associated with **10% mortality risk increase**⁷
- **60%** more likely to develop **dementia** after surviving delirium in the ICU⁸

Unmet Need

- Current diagnosis tool (CAM-ICU) is dependent on nurse training, **binary**, and typically only administered **once or twice per day**

1. Oh E.S., et al. JAMA. 2017 Sep 26;318(12):1161–1174

2. Lindroth H., et al. J Acad Consult Liaison Psychiatry, 65 (5) (2024), pp. 417-430

3. Watt J., et al. Journal of general internal medicine 33, no. 4 (2018): 500-509

4. American Delirium Society, <https://www.americandeliriumsociety.org/What-Is-Delirium>

5. Krewulak, K.D., et al. (2018) Crit Care Med 46(12):p 2029-2035


6. Girard, T.D., et al. (2008). Crit Care 12 Suppl 3(Suppl 3):S3

7. Ely EW., et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 291(14):1753–62 (2004)

8. Wang, S. et al. (2024) Alzheimer's & Dementia, 20(1), 278-287.

Delirium & Seizure: A Hidden Clinical Overlap

- Similar presentation
- Very different treatment approaches



1. Frei A.I., et al. (2023) J Neurol. 271(1):231–240

2. Sambin S., et al. (2019) Front Neurol. 10:263

Make EEG a New Vital Sign in Acute Care



Delirium

- Market development and commercial pilot
- **Full launch** in Q4 2026 / Q1 2027



LVO Stroke


- Advance product, clinical, and regulatory development of stroke algorithm



Hardware

- Develop 2nd gen hardware with additional features to support future indications

Pipeline Programs Significantly Expand Ceribell's TAM



*Chart is not to scale. Acute care delirium market estimated by applying preliminary pricing assumptions to estimated patients at risk of delirium, less overlapping seizure patients.

ceribell[®]

The First and Only

FedRAMP[®] High
Authorization

Seizure Detection Algorithm
for Preterm

Seizure Detection Algorithm
for Ages 1+

Delirium Detection Algorithm
FDA Cleared

LVO Monitoring Algorithm
Breakthrough Designation

ceribell[®]

Clarity When It's Critical